Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845204 | 0.89 | GNRHR (0.44) | GNRHRKMT2AGAAL3MBTL1MEN1 | |
| SCHEMBL22845227 | 0.87 | GNRHR (0.44) | GNRHRKMT2AGAAL3MBTL1MEN1 | |
| SCHEMBL22845403 | 0.83 | TP53 (0.45) | GNRHRKMT2AMEN1TP53ALDH1A1 | |
| SCHEMBL22845269 | 0.83 | GNRHR (0.43) | GNRHRKMT2AGAAL3MBTL1MEN1 | |
| SCHEMBL22845374 | 0.82 | GNRHR (0.45) | GNRHRKMT2AGAAL3MBTL1MEN1 | |
| SCHEMBL22845396 | 0.80 | GNRHR (0.44) | GNRHRKMT2AGAAL3MBTL1MEN1 | |
| SCHEMBL22845489 | 0.79 | GNRHR (0.44) | GNRHRKMT2AGAAL3MBTL1MEN1 | |
| SCHEMBL22845307 | 0.74 | CLPP (0.47) | GNRHRKMT2AGAAL3MBTL1MEN1 | |
| SCHEMBL22845486 | 0.70 | GNRHR (0.36) | GNRHRALDH1A1HTTMAPK1 | |
| SCHEMBL13329204 | 0.67 | MEN1 (0.44) | KMT2AGAAL3MBTL1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GNRHR 2198/4885KMT2A 3917/4885GAA 85/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GNRHR 2198/4885KMT2A 3917/4885GAA 85/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GNRHR 2198/4885KMT2A 3917/4885GAA 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.